France Seeks Stronger Cost-Effectiveness Tools To Lower Drug Prices, But Pan-European Bulk Buying May Come First
Executive Summary
France’s drugs assessment agency wants simpler, stronger rules to evaluate the cost-effectiveness of new drugs. But changes to the country’s complex reimbursement system may be too slow to address immediate budget concerns, making pan-European bulk buying appear a more likely near-term solution.
You may also be interested in...
European Notebook: Drug Pricing Collaborations; Biosimilar Switching; Scientific Advice
Dutch and Belgian health agencies will undertake a pilot project next year on jointly negotiating prices with pharma companies.
Pandemic Spotlights Tensions Between Profit And Philanthropy
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
Virtual Health Care: Where Does This Leave Pharma Marketing?
COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports